Experts at Children's Cancer Institute Australia in Sydney initiated a trial which is said to have boosted the survival rate for children suffering from Acute Lymphoblastic Leukaemia (ALL) to 75 per cent, Australian news agency AAP said today.
"The research would save dozens of young lives in Australia alone," said Glenn Marshall, director of the Kids Cancer Centre at Sydney Children's Hospital Randwick.
"In Australia, each year over 600 kids are diagnosed with cancer or leukaemia and around 150 of those kids won't make it, sadly," he said.
Children at a high risk of relapsing were then treated with an intensive chemotherapy protocol.
Marshall said 1000 children had been involved in the research in Australia, New Zealand and the Netherlands.
"Approximately 30 to 40 children in those countries would not be alive today if we didn't have our trial, because the cure rate for those high-risk patients compared to the 90s has doubled," he said.
"Using this test we could tease out the small population of children at the highest risk of relapse and in fact predict their chance of relapse a long way before it occurred clinically," Marshall said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
